Hsu et al. demonstrated that treatment with the KDM1A inhibitor CBB1003 could significantly inhibit the proliferation and clone-forming ability of CRC cells through inhibition of LGR5 (leucine-rich repeat-containing G-protein-coupled receptor 5), a CRC stem cell marker and Wnt signaling target, suggesting that KDM1A may affect the growth of CRC cells and the maintenance of CSCs through the modulation of key molecules in the Wnt/β-catenin signaling pathway [88]. Here, KDM1A is linked to colorectal carcinoma.